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Objectives: We aimed to investigate the virological and clinical characteristics and the results of
combination therapy in six oncology patients with hepatitis B virus (HBV)—hepatitis C virus (HCV)
co-infection.
Method: Six patients (five male and one female; age range 8—14 years), diagnosed with HBV—
HCV infections during follow-up at the oncology outpatient clinic during 2000—2001 were
included in the study. They had received an average of 25.8 units of blood by transfusion per
patient during their treatment for malignancies. Positive serological HBV indicators were
determined 20—40 months after the end of chemotherapy. HCV RNA positivity was determined
together with HBV at an average of 3.3 months after hepatitis B infection. Patients received
interferon-a-2b and ribavirin for 12 months.
Results: Both HBV DNA and HCV RNA became negative, and anti-HBe became positive in one
patient. One patient had decreased HBV DNA levels and negative HCV RNA and HBeAg, but HBeAg
became positive again at 18-months following treatment. Another patient had decreased serum
HBV DNA and HCV RNA levels with normal ALT levels at the end of treatment; however, two
months after therapy was ceased these values returned to pretreatment levels.
Conclusion: We observed that combined treatment is effective in HBV—HCV infection. The
effectiveness of combined treatment should be researched with larger groups of co-infected
patients.
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Hepatitis B (HBV) and C virus (HCV) infections are the most
common causes of chronic liver disease worldwide. Both arePublished by Elsevier Ltd. All rights reserved.
454 N. Urgancı et al.generally characterized by persistent viremia and chronic
disease, and may progress to cirrhosis or hepatocellular
carcinoma.1,2
HBV and HCV co-infection is not rare. The outcome for
patients with HBV—HCV co-infection is more severe than that
for patients with a single viral infection.3,4 Some studies
carried out in adults have demonstrated that the risk of
progression to cirrhosis or cancer is high in patients with
HBV—HCV co-infection,5—8 while others have shown neither
exacerbation nor diminution of histopathological changes
in patients with HBV—HCV co-infection, and that it has no
role in the progression to cancer.9,10 However, limited data
exist concerning the evolution of HBV—HCV co-infection in
children.3,4,11—13
Adult studies have revealed that in HBV—HCV co-infec-
tions, interferon (IFN) monotherapy is not sufficient,14,15 and
that efficacy might be enhanced with high-dose IFN or riba-
virin (RBV) and lamivudine combinations.16—18 Utili et al.11
reported that IFN is effective in the treatment of HBV—HCV
co-infection in children with malignancies. However, we
could find no data regarding the efficacy of IFN—RBV treat-
ment in children with co-infections.
This study investigates the biochemical, virological, and
histological properties and the response to IFN—RBV therapy
in six children with HBV—HCV co-infection.
Patients and methods
Patients
Six patients diagnosed with HBV during follow-up at the
oncology outpatient clinic during 2000—2001 were included
in the study. We identified HCV infection in 28.6% (20 cases)
of 70 patients with malignancies, and HBV—HCV co-infection
in 8.6% (six cases). Of the six patients, five weremale and one
was female, age 8 to 14 years (11.25  2.07 years). The initial
diagnoses were acute lymphoblastic leukemia (ALL) in four,
acute myeloblastic leukemia (AML) in one, and lymphoma in
one patient (Table 1). All patients were in remission and none
had received chemotherapy for at least 12 months. Each
subject had received an average 25.8 units (6—42 units) of
blood and blood products during treatment. None had a
positive history of liver disease or had received blood or
blood products before the onset of the malignancy. The
children underwent testing for HCV and HBV markers peri-
odically as part of a routine procedure every 3 months during
chemotherapy and at the end of treatment. Transaminase





1 10 M ALL 24
2 14 M Lymphoma 20
3 12.5 M ALL 34
4 12 M ALL 28
5 11 M ALL 40
6 8 F AML 26
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemiaHBV serologic indicators were positive at an average of 28.3
months (20—40 months) after the end of treatment for
malignancies. Anti-HCV and HCV RNA were positive at an
average of 3.3 months (2—6 months) after detection of
hepatitis B infection. All patients had chronic HCV—HBV
infection defined by detectable circulating HBV serologic
indicators and HCV RNA for more than 6months. Five patients
completed the treatment. Pretreatment HCV RNA levels
were <1 000 000 copies/mL; all the patients were genotype
1b. Pretreatment HBV DNA levels were >2000 pg/mL.
In all patients, anti-HDV, HIV, and autoimmune hepatitis
indicators were negative and serum copper, ceruloplasmin,
and a-antitrypsin levels were normal.
Informed consent regarding treatment was obtained
from the patients’ parents, after an explanation about
the implications of HCV infection, prior to performing liver
biopsies and initiating treatment.
Biochemical, virologic, and histologic evaluation
HBsAg was measured with the Hepanostika Micro ELISA kit
(Biomerieux, Boxtel, The Netherlands), HBeAg and anti-HBe
with the IgG Vitros ECi system (Ortho-Clinical diagnostic,
Johnson and Johnson Company, Dutra, Brazil), HBV DNA with
the Hybrid Capture method (Digene, Gaithersburg, MD, USA),
anti-HCV antibody with second generation ELISA, and HCV
RNA with the Amplikor HCV Monitor (Roche Diagnostics Corp.
test version 2.0, Indianapolis, IN, USA). The minimum detect-
able value was 100 copies/mL. Genotype was determined by
PCR analysis (InnoLipa HCV II; Innogenetics, Ghent, Belgium).
Genotype classification was done by the system of Simmonds
et al.19 All cases were identified as genotype 1b. HBV DNA,
anti-HBe, HBeAg, and HCV RNA levels were measured at
baseline, at months 3, 6, and 12 during treatment, and every
6 months for 30 months following completion of therapy. All
patients were followed up for 36 months.
Pretreatment liver biopsy samples were reviewed by an
experienced histopathologist. Biopsy samples were defined
in terms of necroinflammatory activity and fibrosis scores
using the Knodell histological activity index (HAI). No liver
biopsy was performed at the end of treatment.
Treatment schedule
Five patients were administered 3 MU/m2 dose subcuta-
neous IFN-a-2b three times weekly and RBV (Schering-
Plough, Las Piadras, Puerto Rico) (800—1000 mg/day, in
two doses, orally) combination therapy for 12 months;C infection
erval between hematooncologic
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had developed.
Definition of response
Follow-up intervals were set as 3 months starting at the
completion of therapy. Treatment results were updated on
April 30, 2005. We considered the HBV and HCV responses
separately.Normalizationof serumALT levelswas considereda
‘biochemical response’, and the combination of negative HCV
RNA together with normal ALT levels at the end of therapywas
considered a ‘virological response’. The maintenance of nor-
mal ALT levels and negative HCV RNA for a minimum of 6
months following completion of therapy was considered a
‘sustained virological response’. A patient without decreased
HCV RNA and ALT values was considered to be a ‘non-respon-
der’.20 For HBV, response to treatment in the HBV patients was
defined on the basis of serumHBV DNA and HBeAg clearance at
the end of treatment, seroconversion to the anti-HBe, and ALT
normalization within an additional 12 months.
Case reports
Case 1
In 1995, the BFM 86 protocol (vincristine, daunorubicin,
L-asparaginase, cyclophosphamide, 6-mercaptopurine, cyto-
sine arabinoside, methotrexate, doxorubicin, and 6-thiogua-
nine) was commenced for a 10 year-old male patient with a
diagnosis of medium risk acute lymphoblastic leukemia. The
patient was in remission after 3 years of chemotherapy.
During chemotherapy he was transfused with blood and blood
products 26 times. Before treatment, during treatment, and
after treatment hepatitis markers were negative. Twenty-
four months following completion of treatment the patient’s
HBsAg and HBeAg were found to be positive with increased
liver enzymes. Anti-HCV was also found to be positive 2
months after this increase in enzymes. After 6 months
observation, a liver biopsy was carried out due to a 6-fold
increase in ALT, HBsAg, HBeAg, HBV DNA, and HCV RNA
positivity. According to Knodell scoring, the patient was
diagnosed as HAI 7 fibrosis 1, and 3 MU/m2 IFN and 15 mg/
kg/day RBV were given for 1 year. At the end of treatment
serum HBV DNA and HCV RNA levels were decreased with











1 +/ 185 2860 677 211 7/
2 +/ 55 2348 813 213 5/
3 +/ 45 3089 851 564 9/
4 +/ 39 2568 716 945 5/
5 +/ 81 3234 647 889 5/
6 +/ 66 3280 546 264 5/
a The patient was not included in the combined treatment.therapy ALT, HBV DNA, and HCV RNA values returned to
pretreatment levels.
Case 2
In 1995, the BFM 86 protocol was commenced in a 14 year-old
male patient with a diagnosis of T-cell lymphoma. His treat-
ment was ended after 3 years due to remission. During
treatment, he was transfused with blood and blood products
six times. Before, during, and after treatment his hepatitis
markers were negative. Twenty months following completion
of treatment, along with increased liver enzymes, his HBsAg
and HBeAg were found to be positive. Anti-HCV was also
found to be positive 3 months after this increase in enzymes.
After 6months observation, a liver biopsy was carried out due
to increased ALT values, HBsAg, HBeAg, HBV DNA, and HCV
RNA positivity. According to Knodell scoring, the patient was
diagnosed as HAI 5 fibrosis 2, and 3 MU/m2 IFN and 15 mg/kg/
day RBV were given for 1 year. At 6 months of treatment, HBV
DNA and HCV RNA levels were decreased. At the end of
treatment there was seroconversion of anti-HBe and HCV
RNA became negative (Table 2). Eighteen months after the
end of treatment these responses still persisted.
Case 3
In 1994, the BFM 86 protocol was commenced in a 13.5 year-
old male patient with a diagnosis of medium risk acute
lymphoblastic leukemia. His treatment was ended after 3
years due to remission. During treatment, he was transfused
with blood and blood products 25 times. Before, during, and
after treatment his hepatitis markers were negative. Thirty-
four months following completion of treatment, along with
increased liver enzymes, his HBsAg and HBeAg were found to
be positive. Anti-HCV was also found to be positive 3 months
after this increase in enzymes. After 3 months observation, a
liver biopsy was carried out due to a 6-fold increase in ALT
values, HBsAg, HBeAg, HBV DNA, and HCV RNA positivity.
According to Knodell scoring, the patient was diagnosed as
HAI 9 fibrosis 4 (Table 2). There was serious fibrosis and
progression to cirrhosis. The patient did not receive com-
bined treatment due to the presence of portal hypertension
symptoms. He is still being followed in the pediatric gastro-
enterology outpatient clinic with a diagnosis of compensated










1 36 +/ 930 10 754
2 39 /+  —
4 a a a a
1 24 +/ 2897 76 820
2 34 / 95 —
4 48 +/ 4321 103 300
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In 1994, the BFM 86 protocol was commenced in a 12 year-old
male patient with a diagnosis of medium risk acute lympho-
blastic leukemia. His treatment was ended after 3 years due
to remission. During treatment, he was transfused with blood
and blood products 28 times. Before, during, and after
treatment his hepatitis markers were negative. Twenty-eight
months following completion of treatment, along with
increased liver enzymes, his HBsAg and HBeAg were found
to be positive. Anti-HCV was also found to be positive 4
months after this increase in enzymes. After 4 months
observation, a liver biopsy was carried out due to increased
ALT values, HBsAg, HBeAg, HBV DNA, and HCV RNA positivity.
According to Knodell scoring, the patient was diagnosed as
HAI 5 fibrosis 1, and 3 MU/m2 IFN and 15 mg/kg/day RBV were
given for 1 year. Since no response to treatment was seen, the
patient was accepted to be a non-responder (Table 2).
Case 5
In 1994, the BFM 86 protocol was commenced in a 12 year-old
male patient with a diagnosis of medium risk acute lympho-
blastic leukemia. His treatment was ended after 3 years due
to remission. During treatment, he was transfused with blood
and blood products 28 times. Before, during, and after
treatment his hepatitis markers were negative. Forty months
following completion of treatment, along with increased
liver enzymes, his HBsAg and HBeAg were found to be posi-
tive. Anti-HCV was also found to be positive 6 months after
this increase in enzymes. After 3 months observation, a liver
biopsy was carried out due to increased ALT values, HBsAg,
HBeAg, HBV DNA, and HCV RNA positivity. According to
Knodell scoring, the patient was diagnosed as HAI 5 fibrosis
2, and 3 MU/m2 IFN and 15 mg/kg/day RBV were given for 1
year. The HBV DNA level was decreased, and HCV RNA and
HBeAg became negative (Table 2). His HBeAg was still nega-
tive 12 months following treatment; however at 18 months
HBeAg was again positive. Response rates at the 30th month
of follow-up showed no change.
Case 6
In 1996, the BFM 90 protocol (vincristine, daunorubicin,
cyclophosphamide, cytosine arabinoside, prednisolone, VP-
16, mitoxantrone, doxorubicin and 6-thioguanine) was com-
menced in an 8 year-old female patient with a diagnosis of
acute myeloblastic leukemia. Her treatment was ended after
2 years due to remission. During treatment, she was trans-
fused with blood and blood products 42 times. Before, dur-
ing, and after treatment her hepatitis markers were
negative. Twenty-six months following completion of treat-
ment, along with increased liver enzymes, her HBsAg and
HBeAg were found to be positive. Anti-HCV was also found to
be positive 2 months after this increase in enzymes. After 3
months observation, a liver biopsy was carried out due to
increased ALT values, HBsAg, HBeAg, HBV DNA, and HCV RNA
positivity. According to Knodell scoring, the patient was
diagnosed as HAI 5 fibrosis 4, and 3 MU/m2 IFN and 15 mg/
kg/day RBV were given for 1 year. Since no response to
treatment was seen, the patient was accepted to be a
non-responder (Table 2).In all patients, side effects such as fever, tremor, muscle
pain, and loss of appetite due to IFN were reversible. Side
effects were not determined other than a 10% decrease in
hemoglobin due to RBV. In all patients, adverse effects
disappeared with the cessation of therapy. Malignancies
did not recur during antiviral therapy.Discussion
Since patients with childhood malignancies are exposed to
numerous transfusions of blood and blood products, they are
susceptible to viruses such as HBV and HCV during treat-
ment.11 In various seroprevalence studies, HBV—HCV co-
infection was found in 21.3—38.2% of cases, and the disease
showed a benign course with no evidence of decompensation
or hepatocellular carcinoma (HCC) over a period of at least 10
years.3,4,11—13 On the other hand, Cesaro et al.4 observed
histological evidence of cirrhosis in 21% of adult patients with
HBV—HCV co-infection, despite the mild course of the dis-
ease. None of these patients showed evidence of an acute
disease and no sub-fulminant events occurred. It is notable
that in one patient (case 3) who did not have significant
differences in serum transaminase, HBV DNA, and HCV RNA
levels compared to the other five cases, serious fibrosis and
progression to cirrhosis was established histopathologically
34 months after treatment for malignancies.
The response to IFN treatment against HCV infection has
been found to be different for co-infected and single-
infected patients.11 Contrary to the findings of Utili
et al.11 IFN alone has been shown to be ineffective in the
long-term suppression of both HCV and HBV replication in
patients with co-infection.14—16 The introduction of nucleo-
side analogues, RBV and lamivudine, for HCV and HBV
infected patients may offer new therapeutic options both
for naive and non-responder patients.21,22 In recent years,
combination therapy with IFN and RBV has been found to
significantly improve the sustained biochemical and virolo-
gical response in pediatric patients with chronic hepatitis
C.23,24 However, their effect in dually infected patients with
hepatitis B and C is unknown. Liu et al.17 have shown that in
hepatitis B and dually infected patients, the combination of
IFN with RBV could achieve sustained HCV clearance in
adults. However, Marrone et al.18 administered IFN plus
lamivudine treatment for dual HBV and HCV infection to
eight young adults with malignancies; they observed an
HCV sustained response in 50% of the cases and seroconver-
sion to anti-HBe in 20% of patients.
We treated all patients who presented with HCV and HBV
infection with IFN plus RBV. Despite the small number of
patients, we obtained a 20% seroconversion to anti-HBe,
cleared serum HBV DNA, and HCV RNA and a 40% end-of-
treatment response in HCV infection. During the observation
period the sustained virological response rates of the
patients did not change.
In conclusion, we observed that combined treatment
seems to be effective in HBV—HCV co-infected patients with
malignancies. Clearance of HBV replication markers in IFN—
RBV treatment was also of interest. Whether it was due to a
response to treatment or due to seroconversion seen in the
natural course of HBV infection could not be explained. When
we reviewed the literature, we could not find data supporting
HBV—HCV co-infection in patients cured of childhood malignancies 457this. Hence further studies with a large number of co-
infected patients are needed to evaluate the effects of
IFN plus RBV treatment.
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